![]() |
We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer, issued 12-Jun-2025 over PR Newswire.
source: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
【說說心理話】照顧者的座右銘:要先照顧自己!爸爸曾經中風、媽媽有腦退化症、哥哥患思覺失調 嘉賓分享經歷► 即睇